Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aimee D.C. Paulussen is active.

Publication


Featured researches published by Aimee D.C. Paulussen.


Journal of Molecular Medicine | 2004

Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.

Aimee D.C. Paulussen; Ronaldus A. H. J. Gilissen; Martin Armstrong; Pieter A. Doevendans; Peter Verhasselt; H.J.M. Smeets; Eric Schulze-Bahr; Wilhelm Haverkamp; Giinter Breithardt; Nadine Cohen; Jeroen Aerssens

Administration of specific drugs may occasionally induce acquired long QT syndrome (aLQTS), a disorder that predisposes to ventricular arrhythmias, typically of the torsade de pointes (TdP) type, and sudden cardiac death. “Forme fruste” mutations in congenital LQTS (cLQTS) genes have been reported repeatedly as the underlying cause of aLQTS, and are therefore considered as an important risk factor. We evaluated the impact of genetic susceptibility for aLQTS through mutations in cLQTS genes. Five cLQTS genes (KCNH2, KCNQ1, SCN5A, KCNE1, KCNE2) were thoroughly screened for genetic variations in 32 drug-induced aLQTS patients with confirmed TdP and 32 healthy individuals. Missense forme frust mutations were identified in four aLQTS patients: D85N in KCNE1 (two cases), T8A in KCNE2, and P347S in KCNH2. Three other missense variations were found both in patients and controls, and are thus unlikely to significantly influence aLQTS susceptibility. In addition, 13 silent and six intronic variations were detected, four of which were found in a single aLQTS patient but not in the controls. We conclude that missense mutations in the examined cLQTS genes explain only a minority of aLQTS cases.


Human Mutation | 2011

MLL2 mutation spectrum in 45 patients with Kabuki syndrome

Aimee D.C. Paulussen; Alexander P.A. Stegmann; Marinus J. Blok; Demis Tserpelis; Crool Posma-Velter; Yvonne Detisch; Eric Smeets; Annemieke M. A. Wagemans; J Schrander; Marie Jose H. van den Boogaard; Jasper J. van der Smagt; Arie van Haeringen; Irene Stolte-Dijkstra; Wilhelmina S. Kerstjens-Frederikse; Grazia M.S. Mancini; Marja W. Wessels; Raoul C. M. Hennekam; Maaike Vreeburg; Joep Geraedts; Thomy de Ravel; Jean-Pierre Fryns; Hubert J T Smeets; Koenraad Devriendt; Constance T.R.M. Schrander-Stumpel

Kabuki Syndrome (KS) is a rare syndrome characterized by intellectual disability and multiple congenital abnormalities, in particular a distinct dysmorphic facial appearance. KS is caused by mutations in the MLL2 gene, encoding an H3K4 histone methyl transferase which acts as an epigenetic transcriptional activator during growth and development. Direct sequencing of all 54 exons of the MLL2 gene in 45 clinically well‐defined KS patients identified 34 (75.6%) different mutations. One mutation has been described previously, all others are novel. Clinically, all KS patients were sporadic, and mutations were de novo for all 27 families for which both parents were available. We detected nonsense (n=11), frameshift (n=17), splice site (n=4) and missense (n=2) mutations, predicting a high frequency of absent or non‐functional MLL2 protein. Interestingly, both missense mutations located in the C‐terminal conserved functional domains of the protein. Phenotypically our study indicated a statistically significant difference in the presence of a distinct facial appearance (p=0.0143) and growth retardation (p=0.0040) when comparing KS patients with an MLL2 mutation compared to patients without a mutation. Our data double the number of MLL2 mutations in KS reported so far and widen the spectrum of MLL2 mutations and disease mechanisms in KS.


Journal of Biological Chemistry | 2002

A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency

Aimee D.C. Paulussen; Adam Raes; Gert Matthijs; Dirk J. Snyders; Nadine Cohen; Jeroen Aerssens

The congenital long QT syndrome is a cardiac disease characterized by an increased susceptibility to ventricular arrhythmias. The clinical hallmark is a prolongation of the QT interval, which reflects a delay in repolarization caused by mutations in cardiac ion channel genes. Mutations in the HERG (human e ther-à-go-go-relatedgene KCNH2 can cause a reduction in IKr, one of the currents responsible for cardiac repolarization. We describe the identification and characterization of a novel missense mutation T65P in the PAS (Per-Arnt-Sim) domain of HERG, resulting in defective trafficking of the protein to the cell membrane. Defective folding of the mutant protein could be restored by decreased cell incubation temperature and pharmacologically by cisapride and E-4031. When trafficking was restored by growing cells at 27 °C, the kinetics of the mutated channel resembled that of wild-type channels although the rate of activation, deactivation, and recovery from inactivation were accelerated. No positive evidence for the formation of heterotetramers was obtained by co-expression of wild-type with mutant subunits at 37 °C. As a consequence the clinical symptoms may be explained rather by haploinsufficiency than by dominant negative effects. This study is the first to relate a PAS domain mutation in HERG to a trafficking deficiency at body temperature, apart from effects on channel deactivation.


Journal of Medical Genetics | 2009

Clinical Spectrum of SIX3-Associated Mutations in Holoprosencephaly: Correlation between Genotype, Phenotype, and Function.

Felicitas Lacbawan; Benjamin D. Solomon; Erich Roessler; Kenia B. El-Jaick; Sabina Domené; Jorge I. Vélez; Ninin Zhou; Donald W. Hadley; Joan Z. Balog; Robert Long; Alan Fryer; Wendy Smith; Said A. Omar; Scott D. McLean; K. Clarkson; A. Lichty; Nancy J. Clegg; Mauricio R. Delgado; Eric Levey; Elaine E. Stashinko; Lorraine Potocki; M. I. VanAllen; Jill Clayton-Smith; Dian Donnai; Diana W. Bianchi; Pétur Benedikt Júlíusson; Pål R. Njølstad; Han G. Brunner; John C. Carey; Ute Hehr

Background: Holoprosencephaly (HPE) is the most common structural malformation of the human forebrain. There are several important HPE mutational target genes, including the transcription factor SIX3, which encodes an early regulator of Shh, Wnt, Bmp and Nodal signalling expressed in the developing forebrain and eyes of all vertebrates. Objective: To characterise genetic and clinical findings in patients with SIX3 mutations. Methods: Patients with HPE and their family members were tested for mutations in HPE-associated genes and the genetic and clinical findings, including those for additional cases found in the literature, were analysed. The results were correlated with a mutation-specific functional assay in zebrafish. Results: In a cohort of patients (n = 800) with HPE, SIX3 mutations were found in 4.7% of probands and additional cases were found through testing of relatives. In total, 138 cases of HPE were identified, 59 of whom had not previously been clinically presented. Mutations in SIX3 result in more severe HPE than in other cases of non-chromosomal, non-syndromic HPE. An over-representation of severe HPE was found in patients whose mutations confer greater loss of function, as measured by the functional zebrafish assay. The gender ratio in this combined set of patients was 1.5:1 (F:M) and maternal inheritance was almost twice as common as paternal. About 14% of SIX3 mutations in probands occur de novo. There is a wide intrafamilial clinical range of features and classical penetrance is estimated to be at least 62%. Conclusions: Our data suggest that SIX3 mutations result in relatively severe HPE and that there is a genotype–phenotype correlation, as shown by functional studies using animal models.


Human Mutation | 2009

The Mutational Spectrum of Holoprosencephaly-Associated Changes within the SHH Gene in Humans Predicts Loss-of-Function Through Either Key Structural Alterations of the Ligand or Its Altered Synthesis

Erich Roessler; Kenia B. El-Jaick; Christèle Dubourg; Jorge I. Vélez; Benjamin D. Solomon; Daniel E. Pineda-Alvarez; Felicitas Lacbawan; Nan Zhou; Maia Ouspenskaia; Aimee D.C. Paulussen; H.J.M. Smeets; Ute Hehr; Claude Bendavid; Sherri J. Bale; Sylvie Odent; Véronique David; Maximilian Muenke

Mutations within either the SHH gene or its related pathway components are the most common, and best understood, pathogenetic changes observed in holoprosencephaly patients; this fact is consistent with the essential functions of this gene during forebrain development and patterning. Here we summarize the nature and types of deleterious sequence alterations among over one hundred distinct mutations in the SHH gene (64 novel mutations) and compare these to over a dozen mutations in disease‐related Hedgehog family members IHH and DHH. This combined structural analysis suggests that dysfunction of Hedgehog signaling in human forebrain development can occur through truncations or major structural changes to the signaling domain, SHH‐N, as well as due to defects in the processing of the mature ligand from its pre‐pro‐precursor or defective post‐translation bi‐lipid modifications with palmitate and cholesterol Published 2009 by Wiley‐Liss, Inc.


Pediatric Research | 2007

Carbamoyl Phosphate Synthetase Polymorphisms as a Risk Factor for Necrotizing Enterocolitis

Rob M. Moonen; Aimee D.C. Paulussen; N Y Souren; Alfons G H Kessels; M Estela Rubio-Gozalbo; Eduardo Villamor

A C-to-A nucleotide transversion (T1405N) in the gene that encodes carbamoyl-phosphate synthetase 1 (CPS1) has been correlated with low plasma concentrations of l-arginine in neonates. As plasma l-arginine concentrations are decreased in premature infants with necrotizing enterocolitis (NEC), we hypothesized that the CPS1 T1405N polymorphism would correlate with the presence of NEC. We analyzed the CPS1 genotypes for the T1405N polymorphism in 17 preterm infants (≤30 wk and <1500 g) with established NEC, 34 preterm infants without NEC, and 25 healthy term infants. Distribution of genotypes did not differ between the NEC population (CC:AC:AA = 70.6%:23.5%:5.9%) and the preterm control group (CC:AC:AA = 41.2%:35.3%:23.5%; p = 0.110) or the term group (CC:AC:AA = 44%:48%:8%; p = 0.228). The C allele frequency was 82.4% in NEC and 58.8% in preterm control infants (p = 0.018) and analysis for linear trend demonstrated that incidence of NEC increased with the number of C alleles (p = 0.037). The CC genotype was associated with an increased risk of NEC in the preterm infants [odds ratio (OR) = 3.43, 95% confidence interval (CI): 1.01–11.49, p = 0.048), when compared with the grouped together AA/AC genotypes. These data suggest that the CPS1 T1405N polymorphism may be associated with the risk of NEC in preterm infants.


Journal of Medical Genetics | 2010

Mutations in ZIC2 in Human Holoprosencephaly: Description of a Novel ZIC2-Specific Phenotype and Comprehensive Analysis of 157 Individuals

Benjamin D. Solomon; Felicitas Lacbawan; Sandra Mercier; Nancy J. Clegg; Mauricio R. Delgado; Kenneth N. Rosenbaum; Christèle Dubourg; Véronique David; Ann Haskins Olney; Lars-Erik Wehner; Ute Hehr; Sherri J. Bale; Aimee D.C. Paulussen; Hubert J T Smeets; Emily Hardisty; Anna Tylki-Szymańska; Ewa Pronicka; Michelle Clemens; Elizabeth McPherson; Raoul C. M. Hennekam; Jin S. Hahn; Elaine E. Stashinko; Eric Levey; Dagmar Wieczorek; Elizabeth Roeder; Chayim Can Schell-Apacik; Carol W. Booth; Ronald L. Thomas; Sue Kenwrick; Derek A. T. Cummings

Background Holoprosencephaly (HPE), the most common malformation of the human forebrain, may be due to mutations in genes associated with non-syndromic HPE. Mutations in ZIC2, located on chromosome 13q32, are a common cause of non-syndromic, non-chromosomal HPE. Objective To characterise genetic and clinical findings in patients with ZIC2 mutations. Methods Through the National Institutes of Health and collaborating centres, DNA from approximately 1200 individuals with HPE spectrum disorders was analysed for sequence variations in ZIC2. Clinical details were examined and all other known cases of mutations in ZIC2 were included through a literature search. Results By direct sequencing of DNA samples of an unselected group of unrelated patients with HPE in our NIH laboratory, ZIC2 mutations were found in 8.4% (49/582) of probands. A total of 157 individuals from 119 unrelated kindreds are described, including 141 patients with intragenic sequence determined mutations in ZIC2. Only 39/157 patients have previously been clinically described. Unlike HPE due to mutations in other genes, most mutations occur de novo and the distribution of HPE types differs significantly from that of non-ZIC2 related HPE. Evidence is presented for the presence of a novel facial phenotype which includes bitemporal narrowing, upslanting palpebral fissures, a short nose with anteverted nares, a broad and well demarcated philtrum, and large ears. Conclusions HPE due to ZIC2 mutations is distinct from that due to mutations in other genes. This may shed light on the mechanisms involved in formation of the forebrain and face and will help direct genetic counselling and diagnostic strategies.


Genetics in Medicine | 2014

Genome-wide karyomapping accurately identifies the inheritance of single-gene defects in human preimplantation embryos in vitro.

Senthilkumar A. Natesan; Alex J. Bladon; Serdar Coskun; Wafa Qubbaj; R. Prates; Santiago Munné; Edith Coonen; J.C.F.M. Dreesen; Servi J.C. Stevens; Aimee D.C. Paulussen; Sharyn Stock-Myer; Leeanda Wilton; Souraya Jaroudi; Dagan Wells; Anthony P.C. Brown; Alan H. Handyside

Purpose:Our aim was to compare the accuracy of family- or disease-specific targeted haplotyping and direct mutation-detection strategies with the accuracy of genome-wide mapping of the parental origin of each chromosome, or karyomapping, by single-nucleotide polymorphism genotyping of the parents, a close relative of known disease status, and the embryo cell(s) used for preimplantation genetic diagnosis of single-gene defects in a single cell or small numbers of cells biopsied from human embryos following in vitro fertilization.Methods:Genomic DNA and whole-genome amplification products from embryo samples, which were previously diagnosed by targeted haplotyping, were genotyped for single-nucleotide polymorphisms genome-wide detection and retrospectively analyzed blind by karyomapping.Results:Single-nucleotide polymorphism genotyping and karyomapping were successful in 213/218 (97.7%) samples from 44 preimplantation genetic diagnosis cycles for 25 single-gene defects with various modes of inheritance distributed widely across the genome. Karyomapping was concordant with targeted haplotyping in 208 (97.7%) samples, and the five nonconcordant samples were all in consanguineous regions with limited or inconsistent haplotyping results.Conclusion:Genome-wide karyomapping is highly accurate and facilitates analysis of the inheritance of almost any single-gene defect, or any combination of loci, at the single-cell level, greatly expanding the range of conditions for which preimplantation genetic diagnosis can be offered clinically without the need for customized test development.Genet Med 16 11, 838–845.


Human Mutation | 2009

The Full Spectrum of Holoprosencephaly-Associated Mutations within the ZIC2 Gene in Humans Predicts Loss-of-Function as the Predominant Disease Mechanism

Erich Roessler; Felicitas Lacbawan; Christèle Dubourg; Aimee D.C. Paulussen; Jos Herbergs; Ute Hehr; Claude Bendavid; Nan Zhou; Maia Ouspenskaia; Sherri J. Bale; Sylvie Odent; Véronique David; Maximilian Muenke

Mutations of the ZIC2 transcription factor gene are among the most common heterozygous variations detected in holoprosencephaly (HPE) patients, a patient group who lack critical midline forebrain specification due to defective embryonic signaling during development. Recent studies indicate that complete deficiency of the related murine Zic2 transcription factor can also be a contributing factor to variable midline deficiencies, presenting during mid‐gastrulation, that could explain similar forebrain anomalies in this model system. Here we collect and summarize all available mutations in the human ZIC2 gene detected in HPE patients (21 published and 62 novel). Our analysis corroborates this mechanism proposed in mice by predicting loss‐of‐function as the likely pathogenetic mechanism common to most, if not all, of these mutations in HPE. Published 2009 Wiley‐Liss, Inc.


Journal of Crohns & Colitis | 2012

Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy

Lennard P. L. Gilissen; Dennis R Wong; L.G.J.B. Engels; Jörgen Bierau; Jaap A. Bakker; Aimee D.C. Paulussen; Mariëlle Romberg-Camps; Arnold Stronkhorst; Paul J. Bus; Laurens P. Bos; P.M. Hooymans; R.W. Stockbrügger; Cees Neef; Ad Masclee

BACKGROUND AND AIMS Therapeutic drug monitoring of active metabolites of thiopurines, azathioprine and 6-mercaptopurine, is relatively new. The proposed therapeutic threshold level of the active 6-thioguanine nucleotides (6-TGN) is ≥235 pmol/8×10(8) erythrocytes. The aim of this prospective cross-sectional study was to compare 6-TGN levels in adult thiopurine tolerant IBD patients with an exacerbation with those in remission, and to determine the therapeutic 6-TGN cut-off level. METHODS Hundred IBD patients were included. Outcome measures were thiopurine metabolite levels, calculated therapeutic 6-TGN cut-off level, CDAI/CAI scores, thiopurine dose and TPMT enzyme activity. RESULTS Forty-one patients had an exacerbation, 59 patients were in remission. In 17% of all patients 6-TGN levels were compatible with non-compliance. The median 6-TGN levels were not significantly different between the exacerbation and remission group (227 versus 263 pmol/8×10(8) erythrocytes, p=0.29). The previous reported therapeutic 6-TGN cut-off level of 235 pmol/8×10(8) erythrocytes was confirmed in this study. Twenty-six of the 41 patients (63%) with active disease had 6-TGN levels below this threshold and 24 of 59 IBD patients (41%) in clinical remission (p=0.04). CONCLUSIONS Thiopurine non-compliance occurs frequently both in active and quiescent disease. 6-TGN levels below or above the therapeutic threshold are associated with a significant higher chance of IBD exacerbation and remission, respectively. These data support the role of therapeutic drug monitoring in thiopurine maintenance therapy in IBD to reveal non-compliance or underdosing, and can be used as a practical tool to optimize thiopurine therapy, especially in case of thiopurine non-response.

Collaboration


Dive into the Aimee D.C. Paulussen's collaboration.

Top Co-Authors

Avatar

Robert Vlietinck

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

N Y Souren

University of Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Catherine Derom

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Edith Coonen

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert Fagard

Catholic University of Leuven

View shared research outputs
Researchain Logo
Decentralizing Knowledge